(Q35755390)

English

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

scientific article published on 26 February 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

Khalid Al-Efraij

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Mohammed A Aljama

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Hagen Fritz Kennecke

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

language of work or name

0 references

publication date

26 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Cancer Medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

864-870

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

A 5-decade analysis of 13,715 carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Induction of Apoptosis in Neuroendocrine Tumors of the Digestive System During Treatment with Somatostatin Analogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

2 October 2017

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

27 July 2018

Current approach to the management of tumoral process in patients with gastrinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

27 July 2018

Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

27 July 2018

Carcinoid TumorsAn analysis of 2837 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

27 July 2018

High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

25 September 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

25 September 2018

A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

25 September 2018

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

25 September 2018

Somatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472209

25 September 2018

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25727756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The malignant carcinoid syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/25727756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carcinoid tumors: a 37-year experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/25727756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://pubmed.ncbi.nlm.nih.gov/25727756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/25727756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CAM4.435

1 reference

https://api.fatcat.wiki/v0/release/gwgi3rskrne4folzvtv3x2hgpy

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_gwgi3rskrne4folzvtv3x2hgpy

1 reference

https://api.fatcat.wiki/v0/release/gwgi3rskrne4folzvtv3x2hgpy

30 July 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

https://api.fatcat.wiki/v0/release/gwgi3rskrne4folzvtv3x2hgpy

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/gwgi3rskrne4folzvtv3x2hgpy

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35755390&oldid=1801397493"